Clario Acquires WCG's Neuroscience-Focused eCOA Business, Bolstering Clinical Trial Capabilities

Clario, a leading technology firm in the clinical trial space, has announced the acquisition of WCG's neuroscience-focused electronic clinical outcome assessment (eCOA) business. This strategic move is set to enhance Clario's offerings in the rapidly evolving field of clinical trials, particularly in neurology, psychiatry, neuropathic pain, and rare diseases.

Expanding eCOA Expertise

The acquisition brings WCG's specialized expertise in neuroscience eCOA services under Clario's umbrella, significantly expanding the company's capabilities in this critical area. Clario CEO Chris Fikry, M.D., emphasized the importance of this move, stating, "WCG's eCOA business has a well-earned reputation for industry-leading expertise in neuroscience. Adding their scientific and operational capabilities to expand our neuroscience capabilities in imaging and digital physiology aligns with Clario's vision to transform lives by unlocking actionable evidence."

Clario's existing eCOA services, built on 25 years of experience, already include a digital multimedia platform. The integration of WCG's neuroscience-focused eCOA business is expected to create a more comprehensive and specialized offering for clients in the pharmaceutical and biotechnology industries.

Strategic Realignment for WCG

For WCG, the divestiture of its eCOA business represents a strategic shift in focus. WCG CEO Sam Srivastava explained that this move will allow the company to concentrate on "connecting sponsors and CROs with sites to accelerate trials through trial design, study review, site activation, and participant recruitment and retention." This realignment suggests a more targeted approach by WCG towards streamlining the early stages of clinical trials and enhancing overall trial efficiency.

Clario's Continued Growth and Innovation

The acquisition of WCG's eCOA business is the latest in a series of strategic moves by Clario to strengthen its position in the clinical trial technology sector. Approximately one year ago, Clario purchased AI software developer ArtiQ, and six months prior to that, it acquired Inofab Health, a manufacturer of ultrasonic sensor spirometer devices.

These acquisitions demonstrate Clario's commitment to expanding its technological capabilities and staying at the forefront of innovation in clinical trial management. By integrating specialized technologies and expertise from various sources, Clario is positioning itself as a comprehensive solution provider for the complex needs of modern clinical trials, particularly in challenging areas such as neuroscience.